Electrocore LLC

Yahoo Finance • 3 days ago

electroCore names Kelly Benning as SVP of Truvaga wellness division

ROCKAWAY, N.J. - electroCore, Inc. (NASDAQ:ECOR), a bioelectronic medicine company with a market capitalization of $32.68 million, has appointed Kelly Benning as Senior Vice President of its consumer wellness division, Truvaga, effective J... Full story

Yahoo Finance • 8 days ago

ELECTROCORE INC (NASDAQ:ECOR) Reports Mixed Q2 2025 Earnings with Revenue Beat but Wider-Than-Expected Loss

ELECTROCORE INC (NASDAQ:ECOR [https://www.chartmill.com/stock/quote/ECOR]) reported its second-quarter 2025 financial results, revealing mixed performance relative to analyst expectations. While revenue slightly surpassed estimates, the co... Full story

Yahoo Finance • 9 days ago

electroCore Announces Second Quarter 2025 Financial Results

Net sales of $7.4 million increased 20% vs. Q2’2024; YTD net sales of $14.1 million increased 22% vs. first half of 2024 Cash, cash equivalents, restricted cash, and marketable securities of $7.4 million as of June 30, 2025 Company to ho... Full story

Yahoo Finance • 10 days ago

electroCore Appoints James C. Theofilos to the Board of Directors

electroCore, Inc. ROCKAWAY, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that James C. Theofilos has been appointed to the Board... Full story

Yahoo Finance • 24 days ago

electroCore to Participate in Upcoming Investor Conferences

ROCKAWAY, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following investor conferences.... Full story

Yahoo Finance • 3 months ago

electroCore, Inc. (ECOR): A Bull Case Theory

We came across a bullish thesis on electroCore, Inc. (ECOR) on Twitter by KyleAdamsStocks. In this article, we will summarize the bulls’ thesis on ECOR. electroCore, Inc. (ECOR)'s share was trading at $6.85 as of May 2nd.Worst States for D... Full story

Yahoo Finance • 4 months ago

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effective in Treating Concussive Symptoms Associated with Mild Traumatic Brain Injuries

ROCKAWAY, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that new data presented at the 2025 International Brain Injury Associati... Full story

Yahoo Finance • 4 months ago

electroCore to Participate at the Needham Virtual Healthcare Conference

ROCKAWAY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Confe... Full story

Yahoo Finance • 5 months ago

electroCore Announces Full Year 2024 Financial Results

Record full year 2024 net sales of $25.2 million increased 57% over $16.0 million for the full year 2023 driven by 85% annual growth of Rx gammaCoreTMin the United States Department of Veteran Affairs and United States Department of Defens... Full story

Yahoo Finance • 5 months ago

electroCore to Participate at Upcoming Investor Conferences

ROCKAWAY, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in two upcoming investor conferences. M... Full story

Yahoo Finance • 2 years ago

Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023

ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Medical Officer, Dr. Peter Staats will host an a... Full story

Yahoo Finance • 2 years ago

electroCore Announces Third Quarter 2023 Financial Results

Record third quarter 2023 net sales of $4.5 million, an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full year 2023 to $15.0 million - $15.5 million Company to host a conference call and... Full story

Yahoo Finance • 2 years ago

electroCore to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum

ROCKAWAY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, is scheduled to attend the Canaccord Ge... Full story

Yahoo Finance • 2 years ago

Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting

ROCKAWAY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced top line data from an abstract being presented as an oral podium presenta... Full story

Yahoo Finance • 2 years ago

electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue

ROCKAWAY, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, announced today that gammaCore therapy will continue to be listed in the United Kingdom’s... Full story

Yahoo Finance • 2 years ago

electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology

ROCKAWAY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related... Full story

Yahoo Finance • 2 years ago

Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress

“VANQUISH” Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH) “NOVIS” Clinical Trial (n=150) of nVNS for the acute treatment of Ischemic Stroke will compl... Full story

Yahoo Finance • 2 years ago

electroCore to Announce Third Quarter Financial Results on Wednesday, November 8

ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third quarter ended Septemb... Full story

Yahoo Finance • 2 years ago

electroCore to Participate in the Lytham Partners Fall 2023 Virtual Investor Conference

ROCKAWAY, N.J., Oct. 05, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will be participating in the Lytham Par... Full story

Yahoo Finance • 2 years ago

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)

ROCKAWAY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of two peer reviewed publications supporting the use of... Full story